Research Links

COVINGTON, La.--(BUSINESS WIRE)--TCA Cellular Therapy, LLC has enrolled its first patient to participate in the U.S. Food and Drug Administration (FDA) first adult stem cell clinical trial to treat spinal cord injuries. Enrollee and Marine Veteran, Matt Cole was paralyzed from the chest down in a 2005 insurgent attack in Iraq.

“I’m very encouraged by the results of the pre-clinical trials and anticipate this may become a significant therapy for these patients in the near future.”
According to the National Spinal Cord Injury Statistical Center (February 2010), it is estimated that up to 311,000 people in the U.S. are living...

By Rob Waters and Molly Peterson - Jul 30, 2010
Geron Corp. said it was cleared by U.S. regulators to proceed with the first human test of an embryonic stem-cell therapy, aimed at patients with spinal-cord injuries. The shares rose 17 percent.

The Food and Drug Administration lifted a clinical hold on the study imposed last August when the company revealed that mice used in experimental work had...

PLAINSBORO, N.J., Jul 9, 2010 (GlobeNewswire via COMTEX) -- Integra LifeSciences Holdings Corporation announced today the launch of DuraGen Plus(R) Dural Regeneration Matrix - Spinal Matrix, an absorbable and sutureless collagen onlay indicated as a dura substitute for the repair of dura mater.

Integra developed the first onlay collagen graft for dural...